

Rodrigo Dienstmann MD., PhD



Rodrigo Dienstmann MD., PhD

PROFESSOR

Molecular classification of gastrointestinal malignancies, Adjuvant and metastatic colon cancer, Gastric cancer Specialist

Currently, he is collaborating in Computational Oncology, Sage Bionetworks, Fred Hutchinson Cancer Center, Seattle, USA; Leader in the Molecular Prescreening Program for Precision Medicine, Vall d'Hebron Institute of Oncology, Spain and principal investigator of several clinical trials. Author and co-author of more than 50 international publications in prestigious journals. Associate Editor in the Journal of Clinical Oncology Precision Oncology and Daily Reports of European Society for Medical Oncology (ESMO) Congress and inviter peer reviewer of prestigious journals such as Jama Oncology, Plos One, Annals of Oncology among others.

Full name: Rodrigo Dienstmann

Country: Spain

Current Position:

- 2015 – present: Principal Investigator, Oncology data Science Group, Vall d'Hebron Institute of Oncology, Spain.
- 2016 – present: Leader, Molecular Prescreening Program for Precision Medicine, Vall d'Hebron Institute of Oncology, Spain.
- 2015 – present: Research Assistant, Computational Oncology, Sage Bionetworks, Fred Hutchinson Cancer Center, Seattle, USA.

Education:

- 1996 – 2001 Medical Doctor at Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
- 2002 – 2003 Internal Medicine, Hospital de Clínicas de Porto Alegre, Brazil.
- 2004 – 2006 Clinical Oncology, Brazilian National Cancer Institute, Rio de Janeiro, Brazil.
- 2006 – 2009 PhD Clinical Research in Oncology, Brazilian National Cancer Institute, Rio de Janeiro, Brazil.
- 2010 – 2012 Molecular Therapeutics Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain.

2013 – 2013 Molecular Pathology Lab, Massachusetts General Hospital, Boston, USA.
2013 – 2015 Computational Oncology, Sage Bionetworks, Seattle, USA
2017 – 2017 Management in healthcare section (Programa de Alta Dirección en Instituciones Sanitarias) IESE Business School, Madrid, Spain.

Experience:

2006 – 2010 Hospital dos Servidores do Estado do Rio de Janeiro, Brazil.
2006 – 2010 Clínicas Oncológicas Integradas, Rio de Janeiro, Brazil.

Scientific Publications:

Number of publications as author or co-author: 79

Books: 1

Book chapters: 5

Recent scientific publications:

CIViC: A knowledge base for expert-crowdsourcing the clinical interpretation of variants in cancer

Griffith M, Spies NC, Krysiak K, Coffman AC, McMichael JF, Ainscough BJ, Rieke DJ, Danos AM, Kujan L, Ramirez CA, Wagner AH, Skidmore ZL, Liu CJ, Jones M, Bilski RL, Lesurf R, Barnell EK, Shah NM, Bonakdar M, Trani L, Matlock M, Ramu A, Campbell KM, Spies GC, Graubert AP, Karthik G, Eldred JM, Larson DE, Walker JR, Chu S, Bryan JN, Good BN, Wu C, Su AI, Dienstmann R, Jones SJM, Bose R, Spencer DH, Wartman LD, Wilson RK, Mardis ER, Griffith OL. *Nat Genetics* 2017;49(2):170-174.

Consensus Molecular Subtyping and the Evolution of Precision Medicine in Colorectal Cancer

Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. *Nat Rev Cancer* 2017;7(2):79-92.

Prediction of overall survival in stage II and III colon cancer beyond the American Joint Commission on Cancer TNM system: a retrospective, pooled biomarker study

Dienstmann R, Mason MJ, Sinicrope FA, Phipps AI, Tejpar S, Nesbakken A, Danielsen SA, Sveen A, Buchanan DD, Clendenning M, Rosty C, Bot B, Alberts SR, Milburn Jessup J, Lothe RA, Delorenzi M, Newcomb PA, Sargent D, Guinney J. *Ann Oncol* 2017;28(5):1023-1031.

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer.

Grasselli J, Elez E, Caratù G, Matito J, Santos C, Macarulla T, Vidal J, Garcia M, Viéitez JM, Paéz D, Falcó E, Lopez Lopez C, Aranda E, Jones F, Sikri V, Nuciforo P,

Fasani R, Tabernero J, Montagut C, Azuara D, Dienstmann R, Salazar R, Vivancos A. *Ann Oncol* 2017 Jun 1;28(6):1294-1301.

Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in Oncology. Garralda E, Dienstmann R, Tabernero J. *Am Soc Clin Oncol Educ Book* 2017;37:210-215.

Personalizing Adjuvant Therapy for Stage II/III Colorectal Cancer. McCleary NJ, Benson AB 3rd, Dienstmann R. *Am Soc Clin Oncol Educ Book* 2017;37:232-245.

Genomic Determinants of Protein Abundance Variation in Colorectal Cancer Cells.

Roumeliotis TI, Williams SP, Gonçalves E, Alsinet C, Del Castillo Velasco-Herrera M, Aben N, Ghavidel FZ, Michaut M, Schubert M, Price S, Wright JC, Yu L, Yang M, Dienstmann R, Guinney J, Beltrao P, Brazma A, Pardo M, Stegle O, Adams DJ, Wessels L, Saez-Rodriguez J, McDermott U, Choudhary JS. *Cell Rep* 2017;20(9):2201-2214.

Cancer: A precision approach to tumour treatment. Dienstmann R, Tabernero J. *Nature* 2017;548(7665):40-41.

Reply to the letter to the editor 'Including lynch syndrome in personalized prognostication and follow-up of stage II and III colon cancer' by Sciallero et al. Dienstmann R, Guinney J. *Annals Oncol* 2017;28(11):2889-2890.

Colorectal cancer Consensus Molecular Subtypes translated to preclinical models uncover potentially targetable cancer-cell dependencies.

Sveen A, Bruun J, Eide PW, Eilertsen IA, Ramirez L, Murumägi A, Arjama MA, Danielsen SA, Kryeziu K, Elez E, Tabernero J, Guinney J, Palmer HG, Nesbakken A, Kallioniemi O, Dienstmann R, Lothe RA. *Clin Cancer Res* 2018;24(4):794-806.

Efficacy of Sym004 in Patients with Metastatic Colorectal Cancer with Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.

Montagut C, Argilés G, Ciardiello F, Poulsen TT, Dienstmann R, Kragh M, Kopetz S, Lindsted T, Ding C, Vidal J, Clausell-Tormos J, Siravegna G, Sánchez-Martín FJ, Koefoed K, Pedersen MW, Grandal MM, Dvorkin M, Wyrwicz L, Rovira A, Cubillo A, Salazar R, Desseigne F, Nadal C, Albanell J, Zagonel V, Siena S, Fumi G, Rospo G, Nadler P, Horak ID, Bardelli A, Tabernero J. *JAMA Oncol* 2018:e175245.

CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.

Smeby J, Sveen A, Merok MA, Danielsen SA, Eilertsen IA, Guren MG, Dienstmann R, Nesbakken A, Lothe RA. *Ann Oncol* 2018; 29(5):1227-1234

Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations.

Tamborero D, Rubio-Perez C, Deu-Pons J, Schroeder MP, Vivancos A, Rovira A, Tusquets I, Albanell J, Rodon J, Tabernero J, de Torres C, Dienstmann R, Gonzalez-Perez A, Lopez-Bigas N. *Genome Med* 2018;10(1):25.

A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations.

Tamborero D, Rubio-Perez C, Muiños F, Sabarinathan R, Piulats JM, Muntasell A, Dienstmann R, Lopez-Bigas N, Gonzalez-Perez A. *Clin Cancer Res* 2018;24(15):3717-3728.

Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer. Dienstmann R, Salazar R, Tabernero J. *Am Soc Clin Oncol Educ Book* 2018;(38):231-238.

Transcriptional subtyping and CD8 immunohistochemistry identify poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy.

Allen WL, Dunne PD, McDade S, Scanlon E, Loughrey M, Coleman H, McCann C, McLaughlin K, Nemeth Z, Syed N, Jithesh P, Arthur K, Wilson R, Coyle V, McArt D, Murray GI, Samuel L, Nuciforo P, Jimenez J, Argiles G, Dienstmann R, Tabernero J, Messerini L, Nobili S, Mini E, Sheahan K, Ryan E, Johnston PG, Van Schaeybroeck S, Lawler M, Longley DB. *JCO Precis Oncol* 2018; Jun 13

Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2. Chang K, Willis JA, Reumers J, Taggart MW, San Lucas FA, Thirumurthi S, Kanth P, Delker DA, Hagedorn CH, Lynch PM, Ellis LM, Hawk ET, Scheet PA, Kopetz S, Arts J, Guinney J, Dienstmann R, Vilar E. *Ann Oncol* 2018;29(10):2061-2067.

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, Ng CKY, Bedard PL, Tortora G, Douillard JY, Van Allen EM, Schultz N, Swanton C, André F, Puztai L. *Ann Oncol* 2018; 29(9):1895-1902

Should next-generation sequencing testing be routinely used in metastatic colorectal cancer?

Dienstmann R, Ciner A, Hochster HS. *Lancet Oncol* 2018;19(11):1434-1435

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.

Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, Gutiérrez-Enríquez S, Ducey M, Ibrahim YH, Gris-Oliver A, Pellegrino B, Bruna A, Guzmán M, Rodríguez O, Grueso J, Bonache S, Moles-Fernández A, Villacampa G, Viaplana C, Gómez P, Vidal M, Peg V, Serres-Créixams X, Dellaire G, Simard J, Nuciforo P, Rubio IT, Dienstmann R, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Déas O, Jonkers J, Masson JY, Cairo S, Judde JG, O'Connor MJ, Díez O, Balmaña J, Serra V. *EMBO Mol Med* 2018;10(12).

Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.

Rodríguez-Freixinos V, Fariñas-Madrid L, Gil-Martin M, Barretina-Ginesta P, Romeo M, Villacampa G, Pardo B, Ahmed H, Recalde S, Piulats JM, Gómez-Plaza MC, Gil-Moreno A, Sala E, Martínez-Román S, Ponce J, Meléndez C, Carballas E, Dienstmann R, Oaknin A. *Gynecol Oncol* 2019;152(2):270-277.